treating adults treating kids Stimulant shortage

“The DEA’s Manufactured Crisis”

Reading now: 451

The following is a personal essay reflecting the opinions of the author.It began with an Adderall shortage in 2022. Today, prescriptions for many stimulant medications used as the first-line treatment of ADHD are consistently and frustratingly difficult to fill.

So it’s unsurprising that ADHD features prominently in the majority of public comments submitted to the Federal Trade Commission (FTC) by stakeholders impacted by long-term medication shortages involved in the treatment of many conditions, including cancer.

ADHD patients demand attention on their suffering.But, by inviting public testimony on the stimulant shortage and pharmaceutical practices, I believe the FTC is only trying to find cover for the Drug Enforcement Administration (DEA).

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles